NEW YORK, Sept. 9 NeoStem, Inc. (NYSE Amex: NBS) which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today that Alan Harris, M.D., Ph.D., the Company's Vice President of Drug Development and Regulatory Affairs, will speak at a conference on Clinical Applications for Age Management Medicine, taking place in Las Vegas, November 5-8, 2009.
Advertisement
Dr. Harris's presentation will take place during a special pre-conference session on November 5, 2009, focused on "Regenerative Medicine: From Autologous Platelet Derived Growth Factors (PRP) to Stem Cells." The subject of his talk is "The Apheresis Product: A Rich Source of Pluripotent VSELs, Stem Cells and Progenitor Cells for Autologous Banking and Cellular Therapies."
Advertisement
Apheresis utilizes a minimally invasive procedure that members of NeoStem's collection network employ to collect stem cells from peripheral blood to store, using NeoStem's proprietary cryogenic technology, for the donor's personal use in time of medical need. NeoStem also holds a worldwide exclusive license to VSEL (Very Small Embryonic-Like) Cell Technology, and is supporting research programs at the University of Louisville as well as engaging in its own research and development activities. As Vice President of Drug Development and Regulatory Affairs, Dr. Harris oversees the Company's progress in these cutting edge arenas.
The Las Vegas events are organized by the Age Management Medicine Group (AMMG), dedicated to educating physicians and healthcare professionals on this growing medical specialty, age management medicine, through evidence-based scientific medical education conferences, workshops, seminars, publications and Web media. The Group, now in its fifth year, consists of leading industry healthcare professionals, physicians, practitioners, researchers, medical associations and providers of products and services. Attending the conference will be physicians, researchers, and health professionals, including dentists, chiropractors, nurses, physician assistants, nurse practitioners, pharmacists, psychologists and medical students.
Age management medicine is a proactive, preventive approach focused on preservation of optimum human function and quality of life, making every effort to modulate the process of aging prior to the onset of degenerative aging. The basic tenets of age management medicine are patient evaluation through extensive medical history, lifestyle assessment, physical examination and laboratory evaluation to establish personalized proactive treatment plans consisting of proper diet, exercise, stress management and appropriate medical interventions.
About NeoStem, Inc.
NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells and is pursuing other technologies to advance its position in the field of stem cell tissue regeneration. In 2009, the Company began to expand its operations into China in connection with the development of therapeutic adult stem cell technologies and is seeking to generate revenues through its regenerative medicine programs and technologies in China. For more information, please visit: www.neostem.com.
www.neostem.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and the Company's other periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
CONTACT: NeoStem, Inc. Robin Smith, Chief Executive Officer T: 212-584-4180 E: [email protected]
SOURCE NeoStem, Inc.
